Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$19.95 USD

19.95
684,543

-0.05 (-0.25%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $19.95 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Why Is Catalyst (CPRX) Up 4.4% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst's (CPRX) Q3 Earnings Beat Estimates, Revenues Miss

Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.

Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.10%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.

Why Is Catalyst (CPRX) Down 7.5% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst (CPRX) Eyes Firdapse Label Expansion Amid Competition

Catalyst's (CPRX) efforts to expand Firdapse label are encouraging. However, with only a few candidates in the pipeline, the company's dependence on Firdapse for growth remains a matter of concern.

Catalyst's (CPRX) Q2 Earnings & Revenues Beat Estimates

Catalyst (CPRX) beats both earnings and sales estimates in the second quarter of 2020.

Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 12.50% and 2.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Catalyst Pharmaceutical (CPRX) Q2 Earnings Expected to Decline

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst (CPRX) Down 0.4% Since Last Earnings Report: Can It Rebound?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss

Catalyst (CPRX) beats on Q1 earnings but misses on revenues. It also withdraws sales guidance due to the coronavirus pandemic.

Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 11.11% and -8.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Catalyst (CPRX) Up 52.1% Since Last Earnings Report: Can It Continue?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst's (CPRX) Q4 Earnings Miss Estimates, Revenues Meet

Catalyst's (CPRX) earnings lag estimates in the fourth quarter. Revenues match the same.

Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Catalyst (CPRX) Stock We Don't?

Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.

Implied Volatility Surging for Catalyst (CPRX) Stock Options

Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.

Catalyst Gives Preliminary Firdapse Estimates & Other Updates

Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.

Why Is Catalyst (CPRX) Down 5.3% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst Focuses on Firdapse Label Expansion Amid Competition

Catalyst (CPRX) focuses on the development of Firdapse for additional indications.

Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss

Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2019.

Catalyst Pharmaceutical (CPRX) Beats Q3 Earnings Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 18.18% and -8.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store?

During Catalyst's (CPRX) third-quarter 2019 conference call, investor focus will be on the sales performance of its only marketed drug Firdapse and its label expansion studies.

Benjamin Rains headshot

Investors Can Find Strong Stocks with our First Profit Screen

Today, we are utilizing our 'First Profit' stock screen to help investors find strong stocks. The idea is to search for companies that just reported their first quarterly profit within the last year...

Benjamin Rains headshot

Learn How to Find Top-Ranked 'Cheap' Stocks Under $10 with this Screener

Searching for 'cheap' stocks that look poised to climb can be an attractive investment strategy. But investors have to know where and how to find strong stocks trading under $10 a share. So check out this Zacks Stock Screener...